Literature DB >> 11743951

Significance of the variant and full-length forms of the very low density lipoprotein receptor in brain.

Y Nakamura1, M Yamamoto, E Kumamaru.   

Abstract

The very low density lipoprotein receptor (VLDLR) is a newly described receptor which binds to apolipoprotein E (apoE) specifically. The authors designed a synthetic peptide of 17 amino acids representing the N-terminus of the putative first ligand binding domain of human VLDLR, this being a unique domain for VLDLR. When the synthetic peptide was used as the antigen, two different monoclonal antibodies were obtained (anti-VLDLR1 and anti-VLDLR2). Expressional cloning revealed that anti-VLDLR1 recognized the variant form of VLDLR which lacks 84 bp of O-linked sugar domain and anti-VLDLR2 recognized the full length form of VLDLR. The variant VLDLR was expressed in neuroblasts as well as matrix cells and Cajal-Retzius cells in the early stages of the developing human brain; later its expression was sequentially found in glioblasts, astrocytes, oligodendrocytes and finally in myelin. The expression of a full length form of VLDLR was detected in senile plaques and some neurons and satellite glia in aged and Alzheimer brains. This suggests that the variant VLDLR is important for the developing human brain and the full length VLDLR has modified functions in aged and Alzheimer brains.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11743951     DOI: 10.1016/s0006-8993(01)03170-5

Source DB:  PubMed          Journal:  Brain Res        ISSN: 0006-8993            Impact factor:   3.252


  7 in total

1.  Variations of very low-density lipoprotein receptor subtype expression in gastrointestinal adenocarcinoma cells with various differentiations.

Authors:  Tao Chen; Fan Wu; Feng-Ming Chen; Jun Tian; Shen Qu
Journal:  World J Gastroenterol       Date:  2005-05-14       Impact factor: 5.742

2.  A neuronal VLDLR variant lacking the third complement-type repeat exhibits high capacity binding of apoE containing lipoproteins.

Authors:  Keiko Sakai; Oliver Tiebel; M Cecilia Ljungberg; Merry Sullivan; Hye-Jeong Lee; Tomoya Terashima; Rongying Li; Kunihisa Kobayashi; Hui-Chen Lu; Lawrence Chan; Kazuhiro Oka
Journal:  Brain Res       Date:  2009-04-22       Impact factor: 3.252

3.  Up-regulated expression of type II very low density lipoprotein receptor correlates with cancer metastasis and has a potential link to β-catenin in different cancers.

Authors:  Lei He; Yanjun Lu; Peng Wang; Jun Zhang; Chuanchang Yin; Shen Qu
Journal:  BMC Cancer       Date:  2010-11-03       Impact factor: 4.430

4.  Similarities and differences in structure, expression, and functions of VLDLR and ApoER2.

Authors:  Sunil S Reddy; Teal E Connor; Edwin J Weeber; William Rebeck
Journal:  Mol Neurodegener       Date:  2011-05-09       Impact factor: 14.195

Review 5.  The Reelin Receptors Apolipoprotein E receptor 2 (ApoER2) and VLDL Receptor.

Authors:  Paula Dlugosz; Johannes Nimpf
Journal:  Int J Mol Sci       Date:  2018-10-09       Impact factor: 5.923

Review 6.  Emerging Evidence of Pathological Roles of Very-Low-Density Lipoprotein (VLDL).

Authors:  Jih-Kai Huang; Hsiang-Chun Lee
Journal:  Int J Mol Sci       Date:  2022-04-13       Impact factor: 6.208

7.  Differential gene expression in ADAM10 and mutant ADAM10 transgenic mice.

Authors:  Claudia Prinzen; Dietrich Trümbach; Wolfgang Wurst; Kristina Endres; Rolf Postina; Falk Fahrenholz
Journal:  BMC Genomics       Date:  2009-02-05       Impact factor: 3.969

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.